ContractSecurities Agreement • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments
NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
SUBSCRIPTION AGREEMENTSubscription Agreement • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Oregon
This SUBSCRIPTION AGREEMENT (the "Agreement") is made by and between the subscriber hereto (the “Subscriber”) and Calypte Biomedical Corporation, a Delaware corporation (the "Company”).
SIXTH AMENDMENT TO 2005 CREDIT FACILITYCredit Facility Agreement • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
THIS SIXTH AMENDMENT TO 2005 CREDIT FACILITY AGREEMENT (this "Amendment") is made as of March 21, 2007, by and among Calypte Biomedical Corporation, a Delaware corporation ("Issuer"), and Marr Technologies, BV, a limited liability company established in the Netherlands ("Purchaser"). Unless otherwise defined herein, all capitalized terms used herein shall have the meanings given to them in the Credit Facility referred to below.
AMENDMENT TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured 8% Convertible Promissory Notes • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
THIS AMENDMENT (this "Amendment") to Secured 8% Convertible Promissory Notes (the "Notes") is made as of March 21, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and Morningtown Limited, a limited liability company established in Mauritius (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
AMENDMENT TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured Convertible Promissory Note Amendment • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
THIS AMENDMENT (this "Amendment") to Secured 8% Convertible Promissory Notes (each, a “Note,” and collectively, the "Notes") is made as of March 21, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and Marr Technologies BV, a limited liability company established in the Netherlands (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
AMENDMENT TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured 8% Convertible Promissory Notes • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
THIS AMENDMENT (this "Amendment") to Secured 8% Convertible Promissory Notes (the "Notes") is made as of March 21, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and SF Capital Partners Ltd. (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Oregon
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 28, 2007, by and among Calypte Biomedical Corporation, a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Investor” and collectively, the “Investors”).
